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ABSTRACT. he cyclic undecapeptide, cyclosporin (Cs) H, is  a  potent inhibitor  of FMLP-induced superoxide anion 
(02-) formation  in human  neutrophils. We studied the effects of CsH in comparison with those of N-t- 
butoxycarbonyl-~-phenylalanyl-~-leucyl-~-phenyialanyl-~-ieucyi-~-phenylalanine IBocPLPLP), a well  known  formyl 
peptide receptor antagonist, and of other Cs on  activation  of  Nh,2'-O-dibutyryl adenosine 3:5'-monophosphate- 
differentiated HL-60 cells and human erythroleukemia cells (HEL cells). CsH inibited FMLP binding in HL-60 
membranes with a Ki (inhibition constant) of 0.10 pM. CsH inhibited activation by FMLP of high affinity GTPase 
(the  enzymatic activity  of a-subunits of heterotrimeric  regulatory  guanine nucleotide-binding proteins) in  HL-60 
membranes with a Ki of 0.79 pM. CsH inhibited the stimulatory effects of FMLP on cytosolic CaL+ concentration 
([CaZ'],), 02- formation, and P-glucuronidase release with K, values of 0.08, 0.24, and 0.45 pM, respectively. 
BocPLPLP was 14-fold less potent than CsH in  inhibiting FMLP binding and 4- to  6-fold less potent than CsH in 
inhibiting FMLP-induced GTP hydrolysis, rises in'[Ca'+],,  02-formation, and 0-glucuronidase release. CsAreduced 
FMLP-induced 02- formation by 20%, but CsB,  CsC,  CsD, and CsE did not. CsA,  CsB,  CsC,  CsD, and CsE did not 
affect FMLP-induced rises in [Ca'+l,. BocPLPLP inhibited leukotriene B4-induced rises in [Ca'+Ii with a K,of 0.33 
pM, whereas CsH showed no  inhibitory effect. CsH and BocPLPLP did not inhibit the rises in  [Ca2+], induced by 
several other stimuli  in  HL-60 cells and HEL cells. Our results show that 1)  CsH is a  more  potent formyl peptide 
receptor antagonist than BocPLPLP; 2) unlike BocPLPLP, CsH is  selective; and 3)  N-methyl-o-valine  which is present 
at position 11 of the amino  acid sequence of CsH but not of other Cs is  crucial for FMLP antagonism. Journal of 
Immunology, 1993, 150: 4591. 
T he chemotactic peptide, FMLP, binds to formyl peptide  receptors in human  and  rabbit  neutrophils and differentiated HL-60  leukemic  cells  and acti- 
vates pertussis toxin-sensitive G-proteins' which possess 
high affinity GTPase activity (for review, see Refs. 1 4 ) .  
G-proteins mediate  activation of phospholipase C with sub- 
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sequent  activation of protein  kinase C and  increase in 
[Ca2+li (1 -4) .  In addition, FMLP stimulates NADPH 
oxidase-catalyzed 0 2 -  formation  and  P-glucuronidase  re- 
lease  from  azurophilic granules  (1-4). Rises in [Ca"], are 
evident with FMLP at much lower concentrations than 
activation of GTPase, 02- formation,  and  enzyme release 
(1-6). Tertiary  butoxycarbonyl  analogs of  FMLP  are well 
known competitive antagonists  at  formyl  peptide  receptors 
and  inhibit chemotactic peptide-induced  cell  activation 
~ 
Abbreviations used in thls paper: C-protein, heterotrlmeric regulatory gua- 
nine  nucleotide-binding  protein; B,, rnax lmd  number of binding sites; 
BtsAMP,  W,2'-O-dibutyryl adenosine  3:5'-monophosphate; ICaL- I , ,  cytoso- 
lic C a L *  concentration; Cs. cytlospor~n; BocPLPLP, N~t-butoxycarbonyl-l-phe- 
erythroleukemra cells: K,>, equilibrium dlssoctmon constant; K , ,  inhibrtlon 
nylalanyl-t-leucyl-~-phenylalanyl-t-leucyl-t-phe~lylalan~ne; HEL cells, human 
constant; LTB?, leukotriene B,: 02-, superoxide anion. 
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Table I 
Amino acid sequence of various Cs” 
c s  1 2  3 4  5 6 7 8 9 1 0  11 
C s A   C ~ - A B U -  S A R - M E L E U - V A L - M E L E U - A L A - D - A L A - M E L E U - M E L E U -  H E V A L  
C s B   C ~ - A L A -  S A R - M E L E U - V A L - M E L E U - A L A - D - A L A - M E L E U - M E L E U -  H E V A L  
C s D   C 9 - V A L -  S A R - M E L E U - V A L - M E L E U - A L A - O - A L A - M E L E U - M E L E U -  H E V A L  
C s E   C 9 - A B U -  S A R - M E L E U - V A L - M E L E U - A L A - D - A L A - M E L E U - M E L E U -  V A L  
C s H   C ~ - A B U -  S A R - M E L E U - V A L - M E L E U - A L A - 0 - A L A - M E L E U - M E L E U - D -  H E V A L  
c s c  C ~ - T H R -  S A R ~ M E L E U - V A L - M E L E U - A L A - D - A L A - H E L E U - M E L E U -  H E V A L  
t-arninobutyric  acid; Sar, sarcoslne; MeLeu, N-methyl-t-leucine; Val, t-valine;  Meval, N-methyl-t-valine; D-MeVal, N-methyl-D-valine; Ala, t-alanine; o-alanine; Thr, 
The  amino  acid sequences of CsA,  CsB,  CsC,  CsD,  CsE, and CsH are shown ( 1  0). Cg, [2S,3R,4R,6~-3-hydroxy-4-methyl-2-rnethylamino-h-octenoic acid; Abu, 
t-threonine. 
(7-9). BocPLPLP is one of the most  potent formyl peptide 
receptor antagonists presently available (8). In  rabbit  neu- 
trophils, the Ki values of BocPLPLP for inhibition of 
FMLP-stimulated azurophilic granule release and  high af- 
finity GTP hydrolysis are 74 and 230 nM, respectively (9). 
The cyclic undecapeptide, CsH, is an analog of CsA (10). 
CsH possesses N-methybvaline at position 11 of the ami- 
no  acid chain, whereas CsA bears N-methyl+-valine (Table 
I) (10). In contrast to CsA, which potently suppresses early 
events in the activation of T and B lymphocytes, CsH is 
without effect (10, 11). In addition to CsA and CsH, other 
structurally related Cs have been isolated from the fungus, 
Tolypodadiam influrum (Table I) (10). We showed recently 
that CsH is a potent inhibitor of FMLP-induced 0 2 -  for- 
mation in  human neutrophils (12). In addition, CsH inhibits 
FMLP binding in HL-60 membranes. Intriguingly, CsH 
does not inhibit neutrophil activation induced by the 
chemoattractants, C5a, platelet-activating factor, and  LTB+ 
Thus, CsH  may be an FMLP antagonist (1 2). These findings 
prompted us to study in detail FMLP antagonism by CsH 
in Bt2cAMP-differentiated HL-60 cells. For comparison, 
we also studied the effects of BocPLPLP and of CsA, CsB, 
CsC, CsD, and CsE. We show here that CsH is a potent and 
selective formyl peptide receptor antagonist. 
Materials and Methods 
Cs were kindly provided by Sandoz (Basel, Switzerland). 
BocPLPLP was from Sigma Chemie (Deisenhofen, Ger- 
many). Stock solutions of Cs (1 mM each) and BocPLPLP 
(10 mM) were prepared in 100% (v/v) DMSO and were 
stored in polypropylene tubes at -20°C under light pro- 
tection for up to 4 wk. Dilutions of Cs and BocPLPLP were 
made immediately before experiments. As a control, ex- 
periments with DMSO (0.1-3.0%, (v/v)) were performed. 
€Tv~L[~H]P (56 Cilmmol) was purchased from Du Pont- 
New England Nuclear (Bad Nauheim, Germany). Sources 
of other materials have been described elsewhere (12-18). 
Cell culture 
HL-60 cells were cultured in suspension culture and  were 
differentiated toward neutrophil-like cells upon incubation 
with Bt,cAMP (0.2 mM) for 48 h (15, 18, 19). Human 
erythroleukemia cells (HEL cells) were cultured in sus- 
pension culture as previously described (17). 
FMLP binding assay 
FMLP binding was performed as described elsewhere ( 12) 
with modifications. In brief, reaction mixtures (100 pl) con- 
tained 30 pg of membrane protein of Bt2cAMP- 
differentiated HL-60 cells, BSA (0.2%, w/v), 50 mM Tris/ 
HCl, pH 7.3, 1 rnM EDTA, and 5 mM MgC12 with or 
without Cs or BocPLPLP. Incubations were conducted for 
30 min at 25°C and  were initiated by the addition of FML- 
r3H]P  at various concentrations. Reactions were terminated 
by rapid filtration through glass fiber filters (Whatman, GF/ 
C) followed by two washes  with 5 ml  of buffer (4OC) con- 
taining 50 mM  TrisMC1,  pH 7.3, 1 mM  EDTA,  and 5 mM 
MgCI2. Filters were dried, and radioactivity was deter- 
mined in a liquid scintillation counter. Specific binding was 
calculated by subtracting the amount of FML[3H]P bound 
in the presence of 10 pM FMLP from the total amount of 
FML[3H]P bound. Unlabeled FMLP was  added to reaction 
mixtures before FMLr3H]P. Nonspecific binding  was less 
than  10% of total binding. 
Measurement of GTPase activity 
GTP hydrolysis was  measured as previously described (16). 
Assay mixtures (100 pl) contained membranes from HL-60 
cells (5.0-7.0 pg of proteidtube), 0.5 p M  [y-32PlGTP (0.1 
@/tube), 0.5 mM MgC12, 0.1 mM EGTA, 0.1 mM ATP, 
1 mM adenosine 5’-(P,y-imido)-triphosphate, 5 mM cre- 
atine phosphate, 40 pg of creatine kinase, 1 mM dithio- 
threitol, and 0.2% (w/v) BSA in 50 mM triethanolamine1 
HCl,  pH 7.4. Reaction mixtures were preincubated for 5 
min  at 25°C in the presence of FMLP at various concen- 
trations with or without CsH or BocPLPLP. Reactions were 
initiated by the addition of [Y-~~PIGTP and were conducted 
for 15 min.  Low  affinity GTP hydrolysis was determined 
in the presence of 50 pM GTP and amounted to 4 %  of 
total GTPase activity. 
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Measurement of [Ca2+li concentrations before the addition of FMLP (30 nM). 
[Ca2+Ii was determined by using the fluorescent dye, Fura- 
2, according to the protocol described in detail by Seifert 
et al. (18). Briefly, HL-60 cells and HEL cells were sus- 
pended  at 5 X lo6 cells/ml in a buffer consisting of (in mM) 
138  NaCl, 6 KCl, 1 MgS04, 1.1  CaC12, 0.1 EGTA, 1 
Na2HP04, 5 NaHC03, 5.5 glucose, 20 HEPESmaOH, pH 
7.4, supplemented with BSA (0.1%, w/v). Cells were in- 
cubated for 1 h at 37°C in the presence of Fura-2/ 
acetoxymethylester (4 pM). Subsequently, cells were di- 
luted with  the above buffer to a final concentration of 0.5 
X lo6 cells/ml and were centrifuged at 250 X g for 10  min 
at 20°C. Cells were suspended at  1.0 X lo6 cells/ml in  the 
above buffer  and  were  kept  at  20°C  until measurement of 
[Ca2+Ii. Fluorescence of cells (1 .O X IO6 cells in 2 ml) was 
determined at  37°C under constant stirring at lo3 rpm by 
using a Ratio I1 spectrofluorometer (Aminco, Silver Spring, 
MD). Cells were incubated for 3 min  with or without Cs or 
BocPLPLP before the addition of stimuli. The excitation 
and emission wavelengths were 340 and 500 nm, respec- 
tively.  Basal [Ca2+Ii values were subtracted from the cor- 
responding peak [Ca2+Ii values stimulated by agonists. 
Basal [Ca2+Ii n freshly loaded HL-60 cells and  HEL cells 
was 115 2 15 nM and 145 ? 25 nM, respectively (mean 
5 SD, three to eight different preparations of cells). Ex- 
periments with HL-60 cells were performed within 4 h after 
loading with the dye; experiments with HEL cells were 
performed within 1 h. Within these times, basal [Ca2+Ii did 
not rise by more  than  20  nM,  and the responsiveness to none 
of the stimuli studied changed significantly. 
Assay for O2 formation 
02- formation was monitored at 550 nm by continuous 
measurement of ferricytochrome C reduction inhibitable by 
superoxide dismutase, with the use of an  Uvikon 810 dual 
beam spectrophotometer (Kontron, Eching, FRG) (14). Re- 
action mixtures (0.5 ml) contained 100 @I fenicytochrome 
C and a buffer consisting of (in mM) 138 NaCl, 6 KCI, 1 
MgC12, 1 CaC12, 5.5 glucose, and 20 HEPESmaOH, pH 
7.4. HL-60 cells (2.5 X IO6 cells) were suspended in the 
solution described above and were incubated for 3 min in 
the absence or presence of Cs or BocPLPLP at 37°C. 02- 
formation was initiated by the addition of  FMLP. Experi- 
ments  were performed in  the absence of cytochalasin B. 
P-Glucuronidase release 
Enzyme release was determined as previously described 
(15). Briefly, Bt2cAMP-differentiated HL-60 cells (5.0 X 
lo6 cells in 0.5 ml) were suspended in the buffer  used for 
the determination of 02- formation. Cells were incubated 
for 5 min  at 37°C in the presence of cytochalasin B 
(5 pg/ml) in  the presence of CsH or BocPLPLP at various 
Reactions were conducted for 10 min  and  were terminated 
by placing the tubes onto melting ice. Reaction mixtures 
were centrifuged at 1000 X g for 10 min  at 4°C. The de- 
terminations of the activities of lactate dehydrogenase and 
P-glucuronidase of supernatant fluids of reaction mixtures 
and of cell lysates were performed as described elsewhere 
( 15). Lactate dehydrogenase release and  basal P-glucuro- 
nidase release amounted to <5% of cellular content (data 
not shown). 
Miscellaneous procedures 
Protein was determined according to Lowry et al. (20). 
[y-32P]GTP was synthesized according to Johnson and 
Walseth (21). HL-60 membranes were prepared as previ- 
ously described (13). Kd and B,, were calculated as de- 
scribed elsewhere (22). EC50 and IC50 values were obtained 
by graphically analyzing concentration-response curves. Kt 
values were calculated according to Cheng and Prusoff 
(23). 
Results 
First, FMLP binding to formyl peptide receptors in HL-60 
membranes was studied. FMLL3H]P was employed at 0.1 
to 30 nM. Analysis of the binding data  in a Scatchard plot 
revealed a single high affinity binding site with a Kd of 
0.70 t 0.08 nM and a B,, of 956 2 45 fmoVmg protein 
(means 2 SD of three experiments, original binding data 
not shown). In agreement with these results, Boulay et al. 
(24) reported on a single class of high affinity binding sites 
(Kd = 1.5-2.0  nM) for a hydrophilic analog of FMLP in 
intact Bt2cAMP-differentiated HL-60 cells. 
The effects of CsH and BocPLPLP on binding of FMLP 
(3 nM) to HL-60 membranes are shown  in Figure 1. CsH 
inhibited agonist binding with an IC5o of 0.7 pM. Boc- 
PLPLP was about 14-fold less potent than CsH. CsB, CsC, 
CsD, and CsE (1 @I each) did not inhibit FMLP binding 
(data not shown). 
Modulation by CsH and BocPLPLP of high affinity 
GTPase was studied (Fig. 2). FMLP stimulated GTP hy- 
drolysis with an EC50 of about 0.1 pM. CsH (1 pM) in- 
creased the EC50 for FMLP to 1 pM without reducing ag- 
onist efficacy. BocPLPLP (10 pM) increased the EC50 for 
FMLP by almost sevenfold. CsH and BocPLPLP did not 
inhibit basal GTP hydrolysis. CsH  and BocPLPLP inhibited 
GTP hydrolysis stimulated by FMLP (100 nM)  with IC5o 
values of 1.3 and 8.1 pM, respectively (Fig. 3). 
The effects of Cs and BocPLPLP on [Ca2+Ii were stud- 
ied. Cs (up to 10 pM) and BocPLPLP (up to 100 pM) did 
not cause damage of Bt2cAMP-differentiated HL-60 cells 
as revealed by trypan blue dye exclusion and lactate de- 
hydrogenase release and did not induce rises in [Ca2+Ii 
(data not shown). FMLP increased [Ca2+Ii with  an ECSo of 
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FIGURE 1. Inhibition by CsH and BocPLPLP of FMLP bind- 
ing to formyl peptide receptors in membranes of Bt,cAMP- 
differentiated HL-60 cells. CsH and BocPLPLP at the indi- 
cated concentrations were  added to reaction mixtures 3 min 
before FMLl3H1P (3 nM) (17 nCi/tube). 0, CsH; ., Boc- 
PLPLP. FMLP binding to membranes in the absence of CsH or 
BocPLPLP  was 758 2 45 fmol/mg protein (mean 2 SD). Data 
shown are the means of assay triplicates; the SD values of the 
data  were  generally <lo% of the  means. Similar  results  were 
obtained in six experiments. 
1.6 nM and a maximum at 10 nM; CsH and BocPLPLP 
shifted the concentration-response curve for FMLP to the 
right without reducing agonist efficacy (data not shown). 
CsH and BocPLPLP inhibited the effect of FMLP (3 nM) 
on [Ca2+Ii with  IC5*  values  of 0.23 and  1.25 p M ,  respec- 
tively (Fig. 4). 
The effects of CsH and BocPLPLP on 02- formation in 
HL-60 cells were studied. FMLP activated 02- formation 
with  an  EC5, of  15-20 nM and a maximum  at 300 nM (data 
not shown). CsH (1 pM) increased the  EC5* for FMLP to 
170 nM without changing its efficacy; BocPLPLP (10 pM) 
increased the EC5* for FMLP 14-fold (data not shown). 
CsH and BocPLPLP inhibited 0 1  formation induced by 
FMLP (30 nM) with ICso values of 0.6 and 2.6 @I, re- 
spectively (Fig. 5). 
The effects of CsH and BocPLPLP on FMLP-induced 
P-glucuronidase release were also studied. FMLP activated 
enzyme release with  an EC50 of 13 nM and a plateau at 0.1 
to 1 pM (data not shown). CsH and BocPLPLP inhibited 
P-glucuronidase release induced by FMLP (50 nM) with 
IC50 values of 2.2  and  8.8 pM, respectively (see Fig. 5). 
To study the specificity of CsH, its effects on [Ca2+Ii and 
02- formation were compared with those of CsA, CsB, 
CsC, CsD, and CsE (Table 11). CsA, CsB, CsC, CsD, and 
CsE differ from CsH  in the amino acid sequence at posi- 
tions 2 or 1 1  (see Table I). Whereas CsH (1 pM) abolished 
the effect of FMLP (1 nM) on [Ca2+li, none of the other 
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FIGURE 2. Effects of CsH and BocPLPLP on basal  and 
FMLP-stimulated high affinity GTP hydrolysis in membranes 
of Bt,cAMP-differentiated HL-60 cells. GTP hydrolysis in 
HL-60 membranes  was determined in the  presence of FMLP 
at various concentrations with CsH (1 pM), BocPLPLP 
(10 pM), or  solvent (control). A, 0, Control; ., CsH. B, 0, 
Control; H, BocPLPLP. Data shown are the means of assay 
quadruplicates; the SD values of the data were generally 
<5% of the means. Similar results were obtained in four 
experiments. 
Cs (1 pM each) was inhibitory. CsB, CsC, CsD, and CsE 
(1 ClM each) did not inhibit 02- formation induced by 
FMLP (50 nM) (see Table 11). CsH and CsA (1 pM each) 
inhibited FMLP-induced 02- formation by about 20% and 
95%, respectively (see Table 11). 
Finally,  the receptor selectivity of CsH  and BocPLPLP 
was studied. HL-60 cells were stimulated with C5a (0.1 
nM), platelet-activating factor (10 nM), ATP (30 nM), UTP 
(30 nM), and histamine (1 pM) (15, 16, 18, 25). Neither 
CsH (1 @I) nor BocPLPLP ( I O  pM) inhibited the stimu- 
latory effects of these stimuli on [Ca2+Ii (data not shown). 
In addition, CsH (1 pM) and BocPLPLP (10 pM) did  not 
inhibit the increases in [Ca2+Ii induced by NaF (10 mM), 
a direct activator of G-proteins (data not shown) (26). Un- 
expectedly, BocPLPLP shifted the concentration-response 
curve for LTB, to the right (Fig. 6). BocPLPLP inhibited 
the rise in [Ca2+Ii induced by LTB, (3 nM)  with  an  IC50 
of 0.73 (Fig. 6). By contrast, CsH did not inhibit LTB4- 
induced rises in [Ca2+Ii (Fig. 6). 
In HEL cells, thrombin, epinephrine (via a2-adreno- 
ceptors) and PGEl induce rises in [Ca2+Ii (17, 27). CsH 
(1 pM) and BocPLPLP (10 pM) did  not inhibit the stim- 
ulatory effects of thrombin (0.1  and 0.3 U/ml), epinephrine 
(0.1 and 1 pM), and PGEl (30 and 100 nM) on [Ca2+Ii (data 
not shown). 
Discussion 
CsH is a competitive formyl peptide receptor antagonist. 
This view is supported by the following findings. CsH shift- 
ed the concentration-response curves for FMLP on high 
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FIGURE 3. Concentration-response curves for  the inhibi- 
tory effects of CsH and BocPLPLP on FMLP-stimulated high 
affinity GTP hydrolysis in membranes of Bt,cAMP-differenti- 
ated HL-60 cells. GTP hydrolysis in HL-60 membranes was 
determined in the presence of FMLP (1 00 nM)  with CsH and 
BocPLPLP at various concentrations. 0, CsH; H, BocPLPLP. 
In the presence of solvent  (control), FMLP (1 00 nM) increased 
GTP hydrolysis by 9.5 ? 1.2 pmol  of P,/mg/min above basal 
enzyme activity. Data shown are referred to the increase in 
GTP hydrolysis stimulated by FMLP and are the means of 
seven experiments performed in quadruplicate; the SD val- 
ues of the data were  generally <5% of  the means. 
affinity GTP hydrolysis, increase in [Ca2+Ii,  02-formation, 
and P-glucuronidase release to the  right (Fig. 2 ) .  The effects 
of CsH on these parameters were concentration-dependent 
(Figs. 3-5).  In addition, CsH inhibited FMLP binding in a 
concentration-dependent manner (Fig. 1). Due to the pure 
competitive FMLP antagonism by CsH, K j  values  were cal- 
culated (Table 111). 
Unlike in HL-60 cells, CsH is a mixed competitive/ 
noncompetitive antagonist to inhibit FMLP-induced 02- 
formation in human neutrophils (12). Thus, the potency of 
CsH in neutrophils and HL-60 cells cannot be compared on 
the basis of K, values. On the basis of ICso values, CsH  is 
about 15-fold more potent in neutrophils than in HL-60 
cells in inhibiting 02- formation induced by FMLP (30 nM) 
(Fig. 5) (1 2 ) .  It remains to be determined whether the dif- 
ferences in the effects of CsH on 02- formation in these cell 
types are due to the expression of different formyl peptide 
receptor subtypes. 
CsH  did  not inhibit the rises in [Ca2'Ii induced by var- 
ious other stimuli, i.e., C5a, platelet-activating factor, 
LTB4, ATP, UTP, histamine, thrombin, epinephrine, and 
PGEl (Fig. 6). Thus, CsH is a selective formyl peptide 
receptor antagonist. Additionally, CsH did not interfere 
with signal transduction processes at the level of G-proteins 
I- 
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FIGURE 4. Concentration-response curves for the inhibi- 
tory effects of CsH and BocPLPLP on FMLP-induced rises in 
[Ca"], in Bt,cAMP-differentiated HL-60 cells. The increases 
in  [Ca2+],  induced  by FMLP (3 nM)  were determined in the 
presence of CsH and BocPLPLP at various concentrations. 
Antagonists or solvent (control) were added to cells 3 min 
before FMLP. 0, CsH; H, BocPLPLP. In the presence of sol- 
vent, FMLP (3  nM) increased [Caz'Ii by 734 ? 48 nM. Data 
shown are referred to this value and are the means of four 
experiments; the SD values of the data were generally <15% 
of the means. 
as the NaF-induced rise  in [Ca2+Ii was not affected. 
Regardless of whether FMLP binding, rises in [Ca2+Ii, 
02- formation, or P-glucuronidase release are considered, 
CsH  is an at least fourfold more potent FMLP antagonist 
than BocPLPLP (Figs. 1-5, Table 111). Unlike CsH, 
BocPLPLP is  not a selective formyl peptide receptor 
antagonist but a mixed FMLP/LTB4 antagonist (Fig. 6). 
The K, of BocPLPLP for inhibition of LTB4-induced  rises 
in [Ca2+Ii was 0.33 pM. Thus, the  potency of BocPLPLP 
at formyl peptide and LTB4 receptors is similar (Figs. 
4 and 6, Table 111). 7-[3-(4-Acetyl-3-methoxy-2-propyl- 
phenoxy)propoxy]-3,4-dihydro-8-propyl- 2 H - 1 -benzopy- 
ran-2-carboxylic acid (SC-4 1930) is another mixed FMLPl 
LTB4 antagonist, but  its  affinity to LTB4 receptors is greater 
than  to formyl peptide receptors (28). 
Both  CsH and BocPLPLP are very hydrophobic peptides 
(8, 10). This biophysical property may be important for 
FMLP antagonism. Interestingly, hydrophobic transmem- 
brane domains are involved in the recognition of ligands at 
G-protein-coupled receptors (29, 30). However, other Cs 
are hydrophobic, too, but devoid of antagonistic properties 
at formyl peptide receptors (Table 11). Apart from being 
hydrophobic peptides, CsH and BocPLPLP do not share 
amino acid sequence similarity (Table I) (8, 10). It cannot 
be excluded, however, that CsH and BocPLPLP possess 
similarities in  the tertiary structure. 
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FIGURE 5. Concentration-response 
curves for the  inhibitory effects of CsH 
and BocPLPLP on FMLP-induced 02- 
formation and &glucuronidase release 
in Bt,cAMP-differentiated HL-60 cells. 
CsH and BocPLPLP at various concen- 
trations or solvent (control) were added 
to reaction  mixtures  before FMLP (30 
nM). 0, CsH; W BocPLPLP. In  the pres- 
ence of solvent, FMLP (30 nM)  induced 
the formation of 3.8 % 0.3 nmol  of 02- 
per 1 O6 cells and the release of 12.6 ? 
0.2% of the cellular  content  of  p-glucu- 
ronidase. Data  shown are referred to 
these values and are the means of four 
experiments; the SD values of the data 
were generally <lo% of  the means. 
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Table I I  
Effects of Cs on FMLP-induced rises in [Caz+l, and Oz- 
formation in 6tZcAMP-differentiated HL-60 cells" 
Addition increase in [Ca2+], 
(nM) 
02- formation 
(nmol/106 cells) 
4.3 * 0.5 
0.3 2 0.2 
3.4 f 0.3d 
4.0 * 0.7' 
4.6 2 0.4c 
3.8 2 0.5' 
4.0 * 0.6c 
Solvent 519 i 68 
CsH Ob 
CsA 536+51' 
CsB 
csc 
494 2 60L 
485 i 62' 
CsD 
CsE 
553 + 64' 
522 f 47' 
The  effects of Cs (1 pM each) on rises in  ICa2+li nduced by FMLP (1 nM) 
and on 0 2 -  formation induced by  FMLP (50 nM) were  studied. Cs or solvent 
(control) were added to reaction mixtures 3 min before FMLP. Data shown are 
the means of assays in triplicate or quadruplicate. Similar results  were obtained 
effects of Cs were assessed statistically using the Wilcoxon test. 
in three  experiments carried out with different preparations of HL-60 cells. The 
b p < 0.01, 
NS. 
p < 0.05. 
In differentiated HL-60 cells, formyl peptide receptors 
couple to G-proteins not only in the presence of  FMLP, but 
also in its absence. This is suggested by the finding that 
pertussis toxin, which uncouples receptors from G-proteins 
by ADP-ribosylation of their a-subunits, substantially re- 
duces basal high affinity GTP hydrolysis (data not shown) 
(6). Intriguingly, certain antagonists at &opioid peptide re- 
ceptors inhibit high  affinity GTP hydrolysis in the absence 
of agonists, i.e., they possess negative intrinsic activity 
(31). In view of these data it was of considerable interest 
to study the effects of CsH and BocPLPLP on basal GTP 
hydrolysis in HL-60 membranes. Neither CsH nor Boc- 
PLPLP reduced basal GTPase activity, indicating that they 
are neutral antagonists, i.e., devoid of negative intrinsic 
activity (Fig. 2). Similar to HL-60 membranes, BocPLPLP 
is a neutral antagonist in rabbit neutrophil membranes (9). 
Bt2cAMP-differentiated HL-60 cells express at least 
two very closely related formyl peptide receptor subtypes 
(24). The fact that FMLP is  much more potent to increase 
[Ca2+Ii than to activate GTPase, 02- formation, and p- 
glucuronidase release may point to the involvement of dif- 
ferent receptor subtypes in the activation of the above func- 
tions. Therefore, we compared the potency ratio CsW 
BocPLPLP for the various parameters (Table 111). With 
regard to all of the above-mentioned parameters CsH was 
four to  six  times  more potent than  BocPLPLP. The differ- 
ences in  potency ratio between the various functions are too 
small to support the involvement of different formyl pep- 
tide receptor subtypes (32). However, as formyl peptide 
receptor subtypes in Bt2cAMP-differentiated HL-60 cells 
differ only  in  few amino acids, their relative affinities for 
CsH and BocPLPLP may  be  very similar (24). 
Formyl peptide receptors in Bt2cAMP-differentiated 
HL-60 cells and rabbit neutrophils possess the same func- 
tions, e.g., activation of high affinity GTPase and of azuro- 
philic granule release (Figs. 2, 3, and 5) (9). Intriguingly, 
formyl peptide receptors in Bt2cAMP-differentiated HL-60 
cells and rabbit neutrophils show only less than 30% amino 
acid identity (33, 34). Thus, one may expect substantial 
pharmacological differences between formyl peptide re- 
ceptors in  both cell types. One important difference is that 
in Bt2cAMP-differentiated HL-60 cells, the potency of 
FMLP and BocPLPLP to activate or inhibit GTPase, and 
azurophilic granule release is about 20- to 25-fold lower 
than in rabbit neutrophils (Fig. 2, Table 111) (9, 15). For 
further analysis of the pharmacologic heterogeneity of 
formyl peptide receptors it would  be desirable to compare 
the effects of CsH and BocPLPLP on separately expressed 
receptor subtypes. 
With regard to FMLP binding, the potency ratio CsW 
BocPLPLP was greater than for the other parameters mea- 
sured (Table 111). Binding experiments were conducted for 
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FIGURE 6. Effects of CsH  and BocPLPLP on LTB,-induced rises in [Ca2'], in Bt2cAMP-differentiated HL-60 cells. Antagonists 
were  added to cells 3 min before LTB4. A, The increases in  [Ca2+],  induced  by LTB4 at various concentrations were assessed 
in the presence of  solvent  (control),  CsH (1 pM) or BocPLPLP (1 0 pM). V, control; 0, CsH; ., BocPLPLP. Open circles designate 
that LTB4 at the  indicated concentrations did  not  induce a rise in  [Ca2+l,. Data  shown are the means of assay triplicates; the 
SD values generally  varied by less than 15% of the means. Similar results were  obtained in three experiments carried out with 
different preparations of  HL-60 cells. B, The increases in  [Ca2+],  induced  by LTB4 (3 nM) were  determined in the presence of 
CsH and BocPLPLP at various  concentrations. Antagonists or solvent (control) were added to cells 3 min before LTB,. 0, CsH; 
W, BocPLPLP. In the presence of solvent, LTB4 (3 nM) increased [Ca2'Ii by 623 * 39 nM. Data shown are referred to these 
values and are the means of four experiments; the SD values of the data were  generally <15%  of the means. 
Table 111 erties of CsH are important for FMLP antagonism. All Cs 
K, values of CsH and BocPLPLP for inhibition of FMLP binding are hydrophobic cyclic undecapeptides which differ in the 
and  functional effects of FMLP in Bt2cAMP-differentiated HL-60 
cells" amino acid sequence at positions 2 and 11 (Table I). In- 
terestingly, CsH is the only Cs which bears N-methyl+ 
K, Values (pM) valine at position 11. By comparison, CsA, CsB, CsC, and 
CsH BocPLPLP CsD possess N-methyl-L-valine,  and CsE bears  L-valine  at 
FMLP binding 0.10 1.46 (14.6) 
this position (Table  I). Exchange of  N-methyl-D-valine  by 
High  affinity GTP hydrolysis 0.79 4.77 (6.0) N-methyl-L-valine or L-valine resulted in complete loss of 
Increase in [Ca2+], 0.08 0.43 (5.4) 
02- formation 
FMLP antagonism (Table 11). Substitution of the D-amino 
0.24 1.04 (4.3) 
f3-Glucuronidase release 0.45 1.82 (4.0) acid by a L-amino acid is associated with a large confor- 
Parameter 
8 K. values were derived from the ICqn values of CsH and BocPLPLP for mational change Of the peptide (lo)' Exchange Of 
inhibition  of FMLP binding and functional effects of FMLP  (Figs. 1-5) and L-aminobutyric acid at position 2 in CSA  by L-alanine 
agonist affinity/potencies (see Results) according to Cheng and Prusoff (23). 
Numbers in parentheses  designate the potency ratio CsH/BocPLPLP. (CsB), L-threonine (CsC), or L-valine (CsD) did not  result 
30 min, whereas all other experiments were conducted for 
times not longer tharl 15 min. The  pH of buffers was 7.3-7.4 
(see Materials and Methods). Interestingly, BocPLPLP is 
not stable, i.e., substantial decomposition of BocPLPLP oc- 
curs after prolonged incubation in  buffer,  pH 7.4 (7). Thus, 
partial degradation of BocPLPLP could explain its rela- 
tively low potency in binding studies in comparison to other 
parameters. 
Among several Cs examined, CsH is the only one which 
shows antagonism at formyl peptide receptors as assessed 
by receptor binding studies and rises in [Ca2' Ji  (Figs. 1 and 
4, Table 11). Thus, the question arises which structural prop- 
in recovery of FMLP antagonism (Tables I and 11). Thus, 
there is a high degree of structural specificity for FMLP 
antagonism of Cs, i.e., the presence of N-methyl-D-valine 
in position 11 is a conditio sine qua non. Synthesis of CsH 
derivatives may provide a more detailed insight into the 
structure/activity relationship for FMLP antagonism of Cs 
and  may result in the identification of more  potent antag- 
onists than CsH. Eventually, highly potent CsH derivatives 
may  be  used as radioligands for formyl peptide receptors. 
Presently, these important tools for the characterization of 
formyl peptide receptors are not available as the affinity of 
both CsH and BocPLPLP is too low  (Fig. 1 ,  Table 111). In 
this context it may  be interesting to  note  that  CsH  is  not  the 
4598 
only naturally occurring formyl peptide receptor antago- 
nist, i.e., a retrovirus-derived hexapeptide is an FMLP an- 
tagonist as  well (35). We anticipate that additional natural 
FMLP antagonists will be identified in plants, fungi, vi- 
ruses, or even bacteria. 
With  regard  to 02- formation, the situation concerning 
the specificity of the effects of Cs is more complicated than 
with regard to FMLP binding and rises in [Ca2+Ii. In  par- 
ticular,  not only CsH but also CsA inhibited, at least to some 
extent, FMLP-induced 02- formation (Table 11). Inhibition 
by CsA of FMLP-induced 02- formation was also reported 
for human neutrophils (12, 36). This effect of CsA may be 
independent of FMLP antagonism as CsA inhibits also 02- 
formation induced by  NaF, y-hexachlorocyclohexane, and 
PMA, i.e., stimuli which act at post-receptor sites (12). 
However, a lack of effect of CsA on PMA-induced 02- 
formation was reported by Janco and English (37). Thus, 
further experimental work is required to understand the 
effects of CsA  on 02- formation. 
In addition to the pharmacologic characterization of 
formyl peptide receptors, could one envisage other poten- 
tial applications of CsH and CsH derivatives? Although 
activation by formyl peptides of neutrophilic cells in vitro 
has been characterized very extensively, much less infor- 
mation is available concerning the role of bacterial and 
endogenous (e.g., mitochondrial) formyl peptides in the 
pathogenesis of inflammatory processes in vivo ( 1 4 ,  38, 
39). One approach to learn more  about the in vivo role of 
formyl peptides is to study the effects of formyl peptide 
receptor antagonists on the course of inflammatory pro- 
cesses in intact organisms. CsH may possess favorable 
properties as a drug for this purpose. Apart from its potency 
and selectivity for formyl peptide receptors, CsH is more 
stable than BocPLPLP (7,40). The polarity of CsAand CsH 
is similar (40). Thus, one can anticipate that  not only CsA 
but also CsH is absorbed after oral administration and 
shows substantial tissue penetration (41). By analogy to 
CsA, CsH would  be expected to be resistant to degradation 
by proteases (IO,  41). Finally, CsH does not affect activa- 
tion of lymphocytes and basophils (10, 42). 
In conclusion, CsH is  a potent and selective formyl pep- 
tide receptor antagonist. CsH, CsH derivatives, and Boc- 
PLPLP may  be important tools for further exploration of the 
functional heterogeneity of formyl peptide receptor sub- 
types. CsH may be a valuable drug to elucidate the still 
poorly defined role of endogenous and bacterial formyl 
peptides in the pathogenesis of inflammatory processes in 
vivo.  Finally, CsH may  be the starting point for the devel- 
opment of a new class of anti-inflammatory drugs, i.e., 
formyl peptide receptor antagonists. 
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